Genotyping of CYP2C9 and VKORC1 in the Arabic Population of Al-Ahsa, Saudi Arabia

Overview

Journal Biomed Res Int

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
General Medicine

Date 2013 Apr 16

PMID 23586031

Citations 12

Authors

Abdullah M Alzahrani

Georgia Ragia

Hamza Hanieh

Vangelis G Manolopoulos

Affiliations

Soon will be listed here.

Abstract

Polymorphisms in the genes encoding CYP2C9 enzyme and VKORC1 reductase significantly influence the dose variability of coumarinic oral anticoagulants (COAs). Substantial inter- and intraethnic variability exists in the frequencies of CYP2C9*2 and *3 and VKORC1 -1639A alleles. However, the prevalence of CYP2C9 and VKORC1 genetic variants is less characterized in Arab populations. A total of 131 healthy adult subjects from the Al-Ahsa region of Saudi Arabia were genotyped for the CYP2C9 *2 and *3 and VKORC1 -1639G>A polymorphisms by PCR-RFLP method. The frequencies of the CYP2C9 *2 and *3 and VKORC1 -1639A alleles were 13.3%, 2.3%, and 42.4%, respectively, with no subjects carrying 2 defective alleles. The frequencies of the CYP2C9 *3 and VKORC1 -1639A alleles were significantly lower than those reported in different Arabian populations. None of the subjects with the VKORC1 -1639AA genotype were carriers of CYP2C9 *1/*3 genotypes that lead to sensitivity to COAs therapy. The low frequency of the CYP2C9 *3 allele combined with the absence of subjects carrying 2 defective CYP2C9 alleles suggests that, in this specific population, pharmacogenetic COAs dosing may mostly rely upon VKORC1 genotyping.

Citing Articles

Frequencies of VKORC1-1639G>A and rs397509427 in Patients on Warfarin and Healthy Syrian Subjects.

Altawil Y, Youssef L Cardiovasc Ther. 2023; 2023:8898922.

PMID: 38045109 PMC: 10689069. DOI: 10.1155/2023/8898922.

Variations in the Frequencies of Polymorphisms in the CYP450s Genes in Eight Major Ethnicities of Iran: A Review of the Human Data.

Neyshaburinezhad N, Ghasim H, Rouini M, Daali Y, Ardakani Y J Pers Med. 2022; 12(11).

PMID: 36579562 PMC: 9697354. DOI: 10.3390/jpm12111848.

Knowledge, Perception, and Application of Pharmacogenomics Among Hospital Pharmacists in Saudi Arabia.

Algahtani M Risk Manag Healthc Policy. 2020; 13:1279-1291.

PMID: 32904476 PMC: 7455604. DOI: 10.2147/RMHP.S267492.

Association between VKORC1 gene polymorphism and warfarin dose requirement and frequency of VKORC1 gene polymorphism in patients from Kerman province.

Soltani Banavandi M, Satarzadeh N Pharmacogenomics J. 2020; 20(4):574-578.

PMID: 31902949 DOI: 10.1038/s41397-019-0146-5.

variants as significant predictors of warfarin dose in Emiratis.

Al-Mahayri Z, Al Jaibeji H, Saab Y, Soliman K, Al-Gazali L, Patrinos G Pharmgenomics Pers Med. 2019; 12:47-57.

PMID: 31114289 PMC: 6489578. DOI: 10.2147/PGPM.S187350.

References

Bozina N, Granic P, Lalic Z, Tramisak I, Lovric M, Stavljenic-Rukavina A . Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population. Croat Med J. 2003; 44(4):425-8. View

Lee S, Kim K, Thi-Le H, Yea S, Cha I, Shin J . Genetic polymorphism of CYP2C9 in a Vietnamese Kinh population. Ther Drug Monit. 2005; 27(2):208-10. DOI: 10.1097/01.ftd.0000153402.91854.42. View

Zuo J, Xia D, Jia L, Guo T . Genetic polymorphisms of drug-metabolizing phase I enzymes CYP3A4, CYP2C9, CYP2C19 and CYP2D6 in Han, Uighur, Hui and Mongolian Chinese populations. Pharmazie. 2012; 67(7):639-44. View

French B, Joo J, Geller N, Kimmel S, Rosenberg Y, Anderson J . Statistical design of personalized medicine interventions: the Clarification of Optimal Anticoagulation through Genetics (COAG) trial. Trials. 2010; 11:108. PMC: 3000386. DOI: 10.1186/1745-6215-11-108. View

Limdi N, Goldstein J, Blaisdell J, Beasley T, Rivers C, Acton R . Influence of CYP2C9 Genotype on warfarin dose among African American and European Americans. Per Med. 2009; 4(2):157-169. PMC: 2756088. DOI: 10.2217/17410541.4.2.157. View

Burian M, Grosch S, Tegeder I, Geisslinger G . Validation of a new fluorogenic real-time PCR assay for detection of CYP2C9 allelic variants and CYP2C9 allelic distribution in a German population. Br J Clin Pharmacol. 2002; 54(5):518-21. PMC: 1874480. DOI: 10.1046/j.1365-2125.2002.01693.x. View

Mirghani R, Chowdhary G, ElGhazali G . Distribution of the major cytochrome P450 (CYP) 2C9 genetic variants in a Saudi population. Basic Clin Pharmacol Toxicol. 2011; 109(2):111-4. DOI: 10.1111/j.1742-7843.2011.00692.x. View

Aynacioglu A, Brockmoller J, Bauer S, Sachse C, Guzelbey P, Ongen Z . Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. Br J Clin Pharmacol. 1999; 48(3):409-15. PMC: 2014334. DOI: 10.1046/j.1365-2125.1999.00012.x. View

Ghanayem B, Bell D, Zhang Z, Kaminsky L, Shenfield G, Miners J . The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics. 1996; 6(4):341-9. DOI: 10.1097/00008571-199608000-00007. View

10.

Xie H, Prasad H, Kim R, Stein C . CYP2C9 allelic variants: ethnic distribution and functional significance. Adv Drug Deliv Rev. 2002; 54(10):1257-70. DOI: 10.1016/s0169-409x(02)00076-5. View

11.

Arvanitidis K, Ragia G, Iordanidou M, Kyriaki S, Xanthi A, Tavridou A . Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population. Fundam Clin Pharmacol. 2007; 21(4):419-26. DOI: 10.1111/j.1472-8206.2007.00510.x. View

12.

Allabi A, Gala J, Desager J, Heusterspreute M, Horsmans Y . Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations. Br J Clin Pharmacol. 2003; 56(6):653-7. PMC: 1884305. DOI: 10.1046/j.1365-2125.2003.01937.x. View

13.

Yoon Y, Shon J, Kim M, Lim Y, Lee H, Park J . Frequency of cytochrome P450 2C9 mutant alleles in a Korean population. Br J Clin Pharmacol. 2001; 51(3):277-80. PMC: 2015024. DOI: 10.1046/j.1365-2125.2001.00340.x. View

14.

Manolopoulos V . Pharmacogenomics and adverse drug reactions in diagnostic and clinical practice. Clin Chem Lab Med. 2007; 45(7):801-14. DOI: 10.1515/CCLM.2007.184. View

15.

Zainuddin Z, Teh L, Suhaimi A, Ismail R . Malaysian Indians are genetically similar to Caucasians: CYP2C9 polymorphism. J Clin Pharm Ther. 2006; 31(2):187-91. DOI: 10.1111/j.1365-2710.2006.00727.x. View

16.

Wadelius M, Chen L, Lindh J, Eriksson N, Ghori M, Bumpstead S . The largest prospective warfarin-treated cohort supports genetic forecasting. Blood. 2008; 113(4):784-92. PMC: 2630264. DOI: 10.1182/blood-2008-04-149070. View

17.

Manolopoulos V, Ragia G, Tavridou A . Pharmacogenomics of oral antidiabetic medications: current data and pharmacoepigenomic perspective. Pharmacogenomics. 2011; 12(8):1161-91. DOI: 10.2217/pgs.11.65. View

18.

Schelleman H, Limdi N, Kimmel S . Ethnic differences in warfarin maintenance dose requirement and its relationship with genetics. Pharmacogenomics. 2008; 9(9):1331-46. DOI: 10.2217/14622416.9.9.1331. View

19.

Tavridou A, Petridis I, Vasileiadis M, Ragia G, Heliopoulos I, Vargemezis V . Association of VKORC1 -1639 G>A polymorphism with carotid intima-media thickness in type 2 diabetes mellitus. Diabetes Res Clin Pract. 2011; 94(2):236-41. DOI: 10.1016/j.diabres.2011.06.021. View

20.

Zand N, Tajik N, Salek Moghaddam A, Milanian I . Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Iranian population. Clin Exp Pharmacol Physiol. 2007; 34(1-2):102-5. DOI: 10.1111/j.1440-1681.2007.04538.x. View